[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:blepharospasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":29,"states":30},"Blepharospasm",3,2,[8,15,21],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT00001208","Botulinum Toxin for the Treatment of Involuntary Movement Disorders",[],"RECRUITING","2026-08-26T02:18:04.640417Z","2026-07-05T18:42:10.718856Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT03042962","Brain Networks in Dystonia",[],"2026-08-26T02:18:54.586325Z","2026-05-13T02:55:06.106270Z",{"nct_id":22,"title":23,"phases":24,"status":26,"updated_at":27,"content_modified":28},"NCT07489430","DaxibotulinumtoxinA for Blepharospasm",[25],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.512807Z",[],[]]